Clínic Hospital
If you are the contact person for this centre and you wish to make any changes, please contact us.
Head of the Cardiology Department at the Hospital Clínic de Barcelona and researcher at the National Centre for Cardiovascular Research (CNIC) and at the August Pi Sunyer Biomedical Research Institute (IDIBAPS)
Psychiatrist and researcher at the Bipolar and Depressive Disorders Unit of the Hospital Clínic de Barcelona
Researcher of the Centre for Biomedical Research in Mental Health Network (CIBERSAM). Head of the Psychiatry and Psychology Department at the Hospital Clínic de Barcelona and lecturer at the University of Barcelona
Assistant Doctor of Psychiatry and postdoctoral researcher at the Bipolar and Depressive Disorders Unit of the Psychiatry and Psychology Department of the Hospital Clínic de Barcelona.
Professor of Medicine at the University of Barcelona and coordinator of the Central Sensitisation Unit at the Hospital Clínic de Barcelona.
Research Professor at IDIBAPS-Hospital Clínic de Barcelona and Scientific Director of CIBEREHD - Carlos III Health Institute
Head of the HIV-AIDS unit, Hospital Clínic-Barcelona
Endocrinologist at the Obesity Unit of the Endocrinology and Nutrition Service of the Hospital Clínic de Barcelona and former member of the Spanish Obesity Society (SEEDO).
Head of the Immunology Service
Clinical psychologist at the Psychiatry and Psychology Service of the Hospital Clínic de Barcelona and member of the research group Imaging of mood and anxiety disorders at IDIBAPS
According to the World Health Organisation (WHO), the prevalence of obesity worldwide has increased by more than 100 % between 1990 and 2022. This reality has been and is constantly reflected in the media, but not always narrated or illustrated in the right way. Here are some tips on how to report on this disease from experts, international guidelines and specialised image banks.
According to a new study published in Science, a machine learning-based artificial intelligence (AI) system - called Mal-ID - can decipher an individual's history of infections and diseases in the immune system. The authors say this provides a powerful tool with the potential to accurately diagnose autoimmune disorders, viral infections and vaccine responses.
A team of US researchers has followed some patients treated with CAR-T therapies in a small clinical trial conducted between 2004 and 2009 to treat children with neuroblastoma, a nerve cell tumor that can have a poor prognosis. At least one of them, a woman who was treated with CAR-T as a child, remains in remission 18 years later, the longest duration of such therapy described to date. The results are published in the journal Nature Medicine.
Exposure to cold and heat could affect adolescents' mental health, according to a study published in JAMA Network Open. The research, led by the Barcelona Institute for Global Health (ISGlobal), was conducted with nearly 5,000 adolescents from the Netherlands (3,934) and Spain (885). The results showed how exposure to environmental temperatures influences psychiatric symptoms such as anxiety, depression, and attention problems.
Science magazine has named lenacapavir as breakthrough of the year. Lenacapavir is an injectable drug that prevents HIV infection for six months with near 100% efficacy. The publication notes its potential to dramatically reduce infections in high-risk populations, but also reminds that global roll-out will depend on affordability, manufacturing agreements and a robust health infrastructure. Approval of the drug is expected by 2025.
CAR-T cell-based treatments have been successful against some blood tumours, but are much less effective for solid tumours. A phase 1 clinical trial has tested their use in 11 children and young adults with diffuse midline glioma, a tumour of the nervous system that is considered incurable. The results, published in the journal Nature, indicate that the treatment improved functional status in nine of the 11 patients. One of the four who showed a strong response is still healthy four years later.
The U.S. FDA has approved a new drug—called Cobenfy—to treat the symptoms of schizophrenia. Unlike traditional treatments, which are based on blocking the effects of dopamine, its mechanism of action simulates the effects of another neurotransmitter, acetylcholine. It is the first drug to be approved with a different mechanism of action in over 70 years.
The regulatory agencies for medicines in the United States and Europe have issued statements informing about a possible risk of developing certain types of tumors following CAR-T cell immunotherapy treatment. What do we know so far? What is the real risk? Does the benefit-risk balance still hold? Has anything changed after these alerts? We answer these questions with expert opinions and the data currently available.
Five out of ten potential treatments move from animal studies to human studies; four to randomised controlled clinical trials; and one in 20 moves on to approval by regulatory agencies, an analysis estimates. Concordance between positive results in animals and in clinical studies is 86%, according to the study, published in PLoS Biology, which pools the findings of 122 published studies on 54 different human diseases.
CAR-T cell therapies may, in some cases, produce tumours secondary to treatment. A few months ago, the US Food and Drug Administration (FDA) said it was assessing this risk. Now, a study conducted at Stanford University Medical Center (USA) has tracked 724 patients who received this type of treatment since 2016. Of these, 14 developed another blood tumour, but only one was a T-cell lymphoma that could be a direct consequence of the therapy. Further analysis ruled out this link. The results are published in the journal NEJM.